The United Kingdom and the United States have signed a landmark trade agreement that will keep no levies on British pharmaceutical shipments being sold in the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to increase spending on pharmaceuticals through the National Health Service (NHS). This pledge guarantees that import taxes on these vital goods will be held at zero for a duration of the next three years.
This development is in response to earlier threats to hike import taxes on patented pharmaceutical imports, with figures discussed as high as 100%.
"This arrangement with the UK bolsters the global environment for cutting-edge drugs and establishes much-needed fairness to American-British medicine commerce," a release declared.
Commercial Importance
Medicines represent one of the the United Kingdom's biggest export categories to the US, which is clearly the primary destination for major British pharmaceutical firms.
Statistics reveal that in the one-year period leading up to the third quarter, the UK shipped drugs totaling £11.1bn to the US. This amount accounted for a significant portion of total UK exports in that timeframe.
"This agreement safeguards work, boosts funding and paves the way for the UK to become a global hub for medical research," the Business and Trade Secretary commented.
Key UK Commitments
The deal involves several key changes from the British government:
- Price Threshold Increase: The UK will raise the affordability limit at which it judges new medicines to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to double overall public funding on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The sum pharmaceutical firms must return to the NHS to control costs will be limited at 15%. Last year, repayments were more than twenty percent.
Industry Background
The pact follows a protracted dispute between the drug companies and the UK government over spending levels and NHS adoption.
These tensions were intensified by assertions that American customers were paying several times more for the identical medicines than patients in the Britain and the EU.
Over the last 18 months, several large manufacturing plans in the UK have been halted or cancelled, while major expansions have been announced toward American operations.
A senior figure acknowledged that the NHS must spend more on medicines, noting that its spending on drugs had shrunk as a share of its total funding over the previous ten-year period.
